Inactive Instrument

News Edge Therapeutics Inc Nasdaq

Equities

US2798701098

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024	08:02am	AQ
PDS Biotechnology Announces Details of Virtual KOL Event	May. 06	AQ
PDS Biotechnology Announces Details of Virtual KOL Event	May. 03	AQ
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer	May. 02	AQ
PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer	May. 02	CI
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer	Apr. 24	AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer	Apr. 23	AQ
B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating	Mar. 28	MT
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	Mar. 28	AQ
Empire Metals targets key milestones in Australia	Mar. 27	AN
Transcript : PDS Biotechnology Corporation, 2023 Earnings Call, Mar 27, 2024	Mar. 27
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	Mar. 27	AQ
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results	Mar. 20	AQ
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®	Mar. 13	AQ
PDS Biotechnology : Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® - Form 8-K	Mar. 13	PU
PDS Biotechnology Corporation Announces Publication of Preclinical Research	Mar. 13	CI
PDS Biotechnology Names Kirk Shepard as Chief Medical Officer	Jan. 22	MT
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer	Jan. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Edge Therapeutics Inc Nasdaq

Equities

US2798701098

Summary

Filters